Published in Wiley Interdiscip Rev Nanomed Nanobiotechnol on August 31, 2013
Polymer nanoparticles mediated codelivery of antimiR-10b and antimiR-21 for achieving triple negative breast cancer therapy. ACS Nano (2015) 1.13
Ultrasound-guided delivery of microRNA loaded nanoparticles into cancer. J Control Release (2015) 0.90
Formulation of Anti-miR-21 and 4-Hydroxytamoxifen Co-loaded Biodegradable Polymer Nanoparticles and Their Antiproliferative Effect on Breast Cancer Cells. Mol Pharm (2015) 0.87
Nanotechnology in radiation oncology. J Clin Oncol (2014) 0.86
Folate Receptor-Targeted Polymeric Micellar Nanocarriers for Delivery of Orlistat as a Repurposed Drug against Triple-Negative Breast Cancer. Mol Cancer Ther (2015) 0.83
Integrity of lipid nanocarriers in bloodstream and tumor quantified by near-infrared ratiometric FRET imaging in living mice. J Control Release (2016) 0.77
Orlistat and antisense-miRNA-loaded PLGA-PEG nanoparticles for enhanced triple negative breast cancer therapy. Nanomedicine (Lond) (2016) 0.77
Nanomedicines for kidney diseases. Kidney Int (2016) 0.75
Gemcitabine and Antisense-microRNA Co-encapsulated PLGA-PEG Polymer Nanoparticles for Hepatocellular Carcinoma Therapy. ACS Appl Mater Interfaces (2016) 0.75
MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59
MicroRNAs: target recognition and regulatory functions. Cell (2009) 92.17
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (1998) 72.56
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 57.23
Silencing of microRNAs in vivo with 'antagomirs'. Nature (2005) 32.56
An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature (2000) 23.17
miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A (2005) 21.51
A species of small antisense RNA in posttranscriptional gene silencing in plants. Science (1999) 19.34
Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol (2007) 17.80
Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect (2005) 17.71
Small silencing RNAs: an expanding universe. Nat Rev Genet (2009) 13.88
Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov (2009) 12.46
Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev (2002) 10.71
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A (2006) 6.90
VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer (2002) 5.96
Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med (2012) 5.92
Strategies for silencing human disease using RNA interference. Nat Rev Genet (2007) 5.19
Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release (2001) 4.81
Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res (2004) 4.56
MicroRNAs as oncogenes. Curr Opin Genet Dev (2005) 4.54
PLGA-based nanoparticles: an overview of biomedical applications. J Control Release (2012) 4.39
Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials (2006) 4.09
Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces (2009) 4.06
Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci U S A (2008) 3.62
Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat Mater (2009) 2.87
Targeted drug delivery to tumors: myths, reality and possibility. J Control Release (2011) 2.69
PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev (2010) 2.23
Nanoparticles for drug delivery in cancer treatment. Urol Oncol (2008) 2.21
Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci U S A (2011) 2.16
Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proc Natl Acad Sci U S A (2012) 1.91
siRNA vs. shRNA: similarities and differences. Adv Drug Deliv Rev (2009) 1.91
Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. Anticancer Res (2009) 1.61
Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. J Control Release (2008) 1.59
Regulation of microRNA by antagomirs: a new class of pharmacological antagonists for the specific regulation of gene function? Am J Respir Cell Mol Biol (2006) 1.47
Nanomedicine based approaches for the delivery of siRNA in cancer. J Intern Med (2010) 1.36
ICAM-1 targeting of doxorubicin-loaded PLGA nanoparticles to lung epithelial cells. Eur J Pharm Sci (2009) 1.29
In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems. Nanomedicine (2010) 1.29
Multifunctional nanoparticles for combined doxorubicin and photothermal treatments. ACS Nano (2009) 1.21
Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines. J Nanobiotechnology (2011) 1.20
Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 3. Therapeutic efficacy and safety studies in ovarian cancer xenograft model. Cancer Chemother Pharmacol (2006) 1.19
Doxorubicin-loaded PLGA nanoparticles by nanoprecipitation: preparation, characterization and in vitro evaluation. Nanomedicine (Lond) (2007) 1.18
Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles. Clin Cancer Res (2008) 1.12
Polymeric nanoparticles for drug delivery. Methods Mol Biol (2010) 1.12
Co-delivery of as-miR-21 and 5-FU by poly(amidoamine) dendrimer attenuates human glioma cell growth in vitro. J Biomater Sci Polym Ed (2010) 1.10
Pharmacokinetics of curcumin-loaded PLGA and PLGA-PEG blend nanoparticles after oral administration in rats. Colloids Surf B Biointerfaces (2012) 1.09
Anticancer activity of cisplatin-loaded PLGA-mPEG nanoparticles on LNCaP prostate cancer cells. Eur J Pharm Biopharm (2007) 1.08
Targeted delivery of antisense inhibitor of miRNA for antiangiogenesis therapy using cRGD-functionalized nanoparticles. Mol Pharm (2010) 1.07
Gadolinium loaded nanoparticles in theranostic magnetic resonance imaging. Biomaterials (2012) 1.07
Pharmacokinetic characteristics and anticancer effects of 5-fluorouracil loaded nanoparticles. BMC Cancer (2008) 1.06
Toxicology and clinical potential of nanoparticles. Nano Today (2011) 1.05
α(V)β(3) integrin-targeted PLGA-PEG nanoparticles for enhanced anti-tumor efficacy of a Pt(IV) prodrug. ACS Nano (2012) 1.00
MicroRNA-based Cancer Therapeutics: Big Hope from Small RNAs. Mol Cell Pharmacol (2010) 0.99
Biological evaluation of 5-fluorouracil nanoparticles for cancer chemotherapy and its dependence on the carrier, PLGA. Int J Nanomedicine (2011) 0.99
Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy. Nanomedicine (2011) 0.99
Efficient chemotherapy of rat glioblastoma using doxorubicin-loaded PLGA nanoparticles with different stabilizers. PLoS One (2011) 0.99
PLGA-based gene delivering nanoparticle enhance suppression effect of miRNA in HePG2 cells. Nanoscale Res Lett (2011) 0.96
Polymer nanoparticle-mediated delivery of microRNA inhibition and alternative splicing. Mol Pharm (2012) 0.96
Both FA- and mPEG-conjugated chitosan nanoparticles for targeted cellular uptake and enhanced tumor tissue distribution. Nanoscale Res Lett (2011) 0.96
The therapeutic efficacy of camptothecin-encapsulated supramolecular nanoparticles. Biomaterials (2011) 0.96
siRNA applications in nanomedicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2010) 0.95
Design of curcumin loaded cellulose nanoparticles for prostate cancer. Curr Drug Metab (2012) 0.94
Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites. J Natl Cancer Inst (1993) 0.93
Developing a highly stable PLGA-mPEG nanoparticle loaded with cisplatin for chemotherapy of ovarian cancer. PLoS One (2011) 0.93
Delivery of MicroRNA-10b with Polylysine Nanoparticles for Inhibition of Breast Cancer Cell Wound Healing. Breast Cancer (Auckl) (2011) 0.91
Cancer cell migration within 3D layer-by-layer microfabricated photocrosslinked PEG scaffolds with tunable stiffness. Biomaterials (2012) 0.91
Influence of surface charge on the potential toxicity of PLGA nanoparticles towards Calu-3 cells. Int J Nanomedicine (2011) 0.91
Characterization of cisplatin cytotoxicity delivered from PLGA-systems. Eur J Pharm Biopharm (2007) 0.90
PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells. Int J Nanomedicine (2012) 0.90
A crucial test. Nat Med (2005) 0.89
The effect of the oral administration of polymeric nanoparticles on the efficacy and toxicity of tamoxifen. Biomaterials (2010) 0.89
EGFR targeted PLGA nanoparticles using gemcitabine for treatment of pancreatic cancer. J Biomed Nanotechnol (2011) 0.88
Nanoparticle-mediated delivery of shRNA.VEGF-a plasmids regresses corneal neovascularization. Invest Ophthalmol Vis Sci (2012) 0.88
Biodegradable nanoparticles of mPEG-PLGA-PLL triblock copolymers as novel non-viral vectors for improving siRNA delivery and gene silencing. Int J Mol Sci (2012) 0.87
Strategies for short hairpin RNA delivery in cancer gene therapy. Expert Opin Biol Ther (2009) 0.87
Bioreducible poly (β-amino esters)/shRNA complex nanoparticles for efficient RNA delivery. J Control Release (2011) 0.86
Mechanistic studies of Gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells. BMC Cancer (2012) 0.86
Pharmacodynamics of cisplatin-loaded PLGA nanoparticles administered to tumor-bearing mice. Eur J Pharm Biopharm (2009) 0.85
Galactosylated chitosan/5-fluorouracil nanoparticles inhibit mouse hepatic cancer growth and its side effects. World J Gastroenterol (2012) 0.84
Chitosan-modified poly(D,L-lactide-co-glycolide) nanospheres for plasmid DNA delivery and HBV gene-silencing. Int J Pharm (2011) 0.83
Polymeric nanoparticles conjugate a novel heptapeptide as an epidermal growth factor receptor-active targeting ligand for doxorubicin. Int J Nanomedicine (2012) 0.83
Superior preclinical efficacy of gemcitabine developed as chitosan nanoparticulate system. Biomacromolecules (2010) 0.83
5-Fluorouracil nanoparticles inhibit hepatocellular carcinoma via activation of the p53 pathway in the orthotopic transplant mouse model. PLoS One (2012) 0.83
Prostate-targeted biodegradable nanoparticles loaded with androgen receptor silencing constructs eradicate xenograft tumors in mice. Nanomedicine (Lond) (2012) 0.81
Development of small interfering RNA delivery system using PEI-PEG-APRPG polymer for antiangiogenic vascular endothelial growth factor tumor-targeted therapy. Int J Nanomedicine (2011) 0.81
Interfering nanoparticles for silencing microRNAs. Methods Enzymol (2012) 0.81
Poly(ethyleneglycol)-b-poly(ε-caprolactone-co-γ-hydroxyl-ε- caprolactone) bearing pendant hydroxyl groups as nanocarriers for doxorubicin delivery. Biomacromolecules (2012) 0.81
Effect of conditions of preparation on the size and encapsulation properties of PLGA-mPEG nanoparticles of cisplatin. Drug Deliv (2007) 0.80
Poly(amidoamine)-Cholesterol Conjugate Nanoparticles Obtained by Electrospraying as Novel Tamoxifen Delivery System. J Drug Deliv (2011) 0.80
Preparation of folate-modified pullulan acetate nanoparticles for tumor-targeted drug delivery. Drug Deliv (2010) 0.79
Low-molecular weight chitosan/vascular endothelial growth factor short hairpin RNA for the treatment of hepatocellular carcinoma. Life Sci (2012) 0.79
Preparation, physicochemical characterization and cytotoxicity in vitro of gemcitabine-loaded PEG-PDLLA nanovesicles. World J Gastroenterol (2010) 0.78
Entrapment of epirubicin in poly(butyl cyanoacrylate) colloidal nanospheres by nanoprecipitation: formulation development and in vitro studies on cancer cell lines. Colloids Surf B Biointerfaces (2011) 0.78
Toxicological aspects for nanomaterial in humans. Methods Mol Biol (2013) 0.78
Tamoxifen-loaded nanoparticles based on a novel mixture of biodegradable polyesters: characterization and in vitro evaluation as sustained release systems. J Microencapsul (2012) 0.77
Improved anti-tumoral capacity of mixed and pure anti-oestrogens in breast cancer cell xenografts after their administration by entrapment in colloidal nanosystems. J Steroid Biochem Mol Biol (2006) 0.77
Development and characterization of hyaluronic acid decorated PLGA nanoparticles for delivery of 5-fluorouracil. Drug Deliv (2010) 0.77
Synthesis and characterization of doxorubicin-loaded poly(lactide-co-glycolide) nanoparticles as a sustained-release anticancer drug delivery system. Appl Biochem Biotechnol (2012) 0.76
Molecular-targeted therapy for cancer and nanotechnology. Methods Mol Biol (2010) 0.76
US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Radiology (2008) 3.15
Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo. Radiology (2008) 1.88
Uptake kinetics and biodistribution of 14C-D-luciferin--a radiolabeled substrate for the firefly luciferase catalyzed bioluminescence reaction: impact on bioluminescence based reporter gene imaging. Eur J Nucl Med Mol Imaging (2008) 1.64
The fate and toxicity of Raman-active silica-gold nanoparticles in mice. Sci Transl Med (2011) 1.50
Imaging gene expression in human mesenchymal stem cells: from small to large animals. Radiology (2009) 1.37
Comparison of optical bioluminescence reporter gene and superparamagnetic iron oxide MR contrast agent as cell markers for noninvasive imaging of cardiac cell transplantation. Mol Imaging Biol (2008) 1.27
Molecular imaging of homodimeric protein-protein interactions in living subjects. FASEB J (2004) 1.17
Oxidative stress mediates the effects of Raman-active gold nanoparticles in human cells. Small (2011) 1.13
Reporter gene imaging of protein-protein interactions in living subjects. Curr Opin Biotechnol (2007) 1.11
Monitoring of the biological response to murine hindlimb ischemia with 64Cu-labeled vascular endothelial growth factor-121 positron emission tomography. Circulation (2008) 1.07
Ultrasound-mediated gene delivery with cationic versus neutral microbubbles: effect of DNA and microbubble dose on in vivo transfection efficiency. Theranostics (2012) 1.05
Cationic versus neutral microbubbles for ultrasound-mediated gene delivery in cancer. Radiology (2012) 1.03
Molecular imaging of the efficacy of heat shock protein 90 inhibitors in living subjects. Cancer Res (2008) 1.03
Antioxidants improve early survival of cardiomyoblasts after transplantation to the myocardium. Mol Imaging Biol (2009) 1.02
Noninvasive imaging of therapeutic gene expression using a bidirectional transcriptional amplification strategy. Mol Ther (2008) 1.02
A molecularly engineered split reporter for imaging protein-protein interactions with positron emission tomography. Nat Med (2010) 1.02
Loss of expression, and mutations of Smad 2 and Smad 4 in human cervical cancer. Oncogene (2003) 0.98
Novel bidirectional vector strategy for amplification of therapeutic and reporter gene expression. Hum Gene Ther (2004) 0.98
The death domain-containing kinase RIP1 regulates p27(Kip1) levels through the PI3K-Akt-forkhead pathway. EMBO Rep (2008) 0.94
Noninvasive molecular imaging of c-Myc activation in living mice. Proc Natl Acad Sci U S A (2010) 0.86
Oxidative stress-mediated cytotoxicity and apoptosis induction by TiO2 nanofibers in HeLa cells. Eur J Pharm Biopharm (2012) 0.83
Imaging cellular receptors in breast cancers: an overview. Curr Pharm Biotechnol (2011) 0.82
Visualization of telomerase reverse transcriptase (hTERT) promoter activity using a trimodality fusion reporter construct. J Nucl Med (2006) 0.82
Reporter protein complementation imaging assay to screen and study Nrf2 activators in cells and living animals. Anal Chem (2013) 0.81
Noninvasive imaging of hypoxia-inducible factor-1α gene therapy for myocardial ischemia. Hum Gene Ther Methods (2013) 0.81
Non-invasive bioluminescence imaging of myoblast-mediated hypoxia-inducible factor-1 alpha gene transfer. Mol Imaging Biol (2011) 0.80
A transgenic tri-modality reporter mouse. PLoS One (2013) 0.80
Intratumoral versus intravenous gene therapy using a transcriptionally targeted viral vector in an orthotopic hepatocellular carcinoma rat model. J Vasc Interv Radiol (2012) 0.79
Noninvasive reporter gene imaging of human Oct4 (pluripotency) dynamics during the differentiation of embryonic stem cells in living subjects. Mol Imaging Biol (2014) 0.79
Dynamic analysis of GH receptor conformational changes by split luciferase complementation. Mol Endocrinol (2014) 0.78
Discovery and validation of small-molecule heat-shock protein 90 inhibitors through multimodality molecular imaging in living subjects. Proc Natl Acad Sci U S A (2012) 0.78
Therapeutic potential of pterostilbene against pancreatic beta-cell apoptosis mediated through Nrf2. Br J Pharmacol (2014) 0.77
Non-invasive imaging of ferucarbotran labeled INS-1E cells and rodent islets in vitro and in transplanted diabetic rats. Curr Pharm Biotechnol (2011) 0.77
Molecular imaging of hypoxia-inducible factor 1 alpha and von Hippel-Lindau interaction in mice. Mol Imaging (2009) 0.76
A titratable two-step transcriptional amplification strategy for targeted gene therapy based on ligand-induced intramolecular folding of a mutant human estrogen receptor. Mol Imaging Biol (2014) 0.76
Genetically encoded molecular biosensors to image histone methylation in living animals. Anal Chem (2014) 0.76
A c-Myc activation sensor-based high-throughput drug screening identifies an antineoplastic effect of nitazoxanide. Mol Cancer Ther (2013) 0.76
Degron protease blockade sensor to image epigenetic histone protein methylation in cells and living animals. ACS Chem Biol (2014) 0.75
Molecular imaging in current pharmaceutical. Curr Pharm Biotechnol (2011) 0.75